SECsense Logo

Lixte Biotechnology Holdings, Inc. 8-K Report: Key Developments & Stock Insights

$LIXT
Form 8-K
Filed on: 2025-01-06
Source
Lixte Biotechnology Holdings, Inc. 8-K Report: Key Developments & Stock Insights

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Filing Entity: The filing is made by Lixte Biotechnology Holdings, Inc. with CIK number 0001335105.
  2. Filing Type: This document is an 8-K, which indicates it reports unscheduled material events or corporate changes that are of importance to shareholders.
  3. Filing Date: The report is dated January 6, 2025.
  4. Stock Information:
  • The company's common stock is traded under the ticker symbol LIXT on NASDAQ.
  • There is also a warrant to purchase common stock, traded under the ticker symbol LIXTW on NASDAQ.
  1. Context Information:
  • The report outlines events and financial information as of January 6, 2025.
  • It specifies two classes of stock: Common Stock and Warrant to Purchase Common Stock.
  1. Units of Measure:
  • Financial measures are reported in USD (U.S. Dollars).
  • The report also includes measures in shares.
  • There is a specification for the financial metric presented as USD per share.
  1. Location: The company is located at 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101.
  2. Contact Information: The contact phone number for the company is (631) 830-7092.

Insights:

  • The 8-K filing indicates that there may have been significant developments at Lixte Biotechnology Holdings that warranted this disclosure. Investors may want to review the full 8-K report for details regarding the events or changes reported.
  • The existence of warrants suggests potential dilution of the common stock, which is a common consideration for investors.
  • The registration on NASDAQ indicates a level of compliance and regulatory oversight, which is an important factor for investor confidence.

Overall, this report serves as a formal communication of material events and should be monitored for any implications on the stock's performance and the company's strategy moving forward.